{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:49:48Z","timestamp":1790232588587,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An explorative study evaluates the efficacy of Helicobacter pylori (HP) eradication (HPE) therapy on early-stage gastric diffuse large B-cell lymphomas (DLBCLs) without features of mucosa-associated lymphoid tissue (MALT), the pure (de novo) DLBCLs, in comparison with its efficacy on high-grade transformed gastric MALT lymphomas, the DLBCL(MALT). In total, 50 patients of stage IE\/IIE1 HP-positive gastric DLBCLs with frontline HPE treatment were included. HP infection was successfully eradicated in 100% (16\/16) of the pure (de novo) DLBCL patients and 94.1% (32\/34) of the DLBCL(MALT) patients. In total, 68.8% (11\/16) of pure (de novo) DLBCL patients and 56.3% (18\/32) of DLBCL(MALT) patients achieved complete pathologic remission (pCR) after HPE therapy. The median time to pCR was 2.1 months (95% confidence interval, 0.6%-3.7%) for pure (de novo) DLBCLs and 5.0 months (95% confidence interval, 2.8%-7.5%; P = .024) for DLBCL(MALT). At a median follow-up of 7.7 years, all patients with pCR after HPE therapy were alive and free of lymphomas, except for one patient with pure (de novo) DLBCL who died of lung cancer. Similar to DLBCL(MALT), a substantial portion of early-stage HP-positive gastric pure (de novo) DLBCLs remains HP-dependent and responds to antibiotic treatment. Prospective studies to validate the findings are warranted.<\/jats:p>","DOI":"10.1182\/blood-2012-01-404194","type":"journal-article","created":{"date-parts":[[2012,3,8]],"date-time":"2012-03-08T00:37:28Z","timestamp":1331167048000},"page":"4838-4844","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":125,"title":["Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori\u2013positive gastric diffuse large B-cell lymphomas"],"prefix":"10.1182","volume":"119","author":[{"given":"Sung-Hsin","family":"Kuo","sequence":"first","affiliation":[{"name":"Departments of Oncology and"},{"name":"Internal Medicine,"},{"name":"Cancer Research Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Huei","family":"Yeh","sequence":"additional","affiliation":[{"name":"Departments of Oncology and"},{"name":"Cancer Research Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ning","family":"Hsu","sequence":"additional","affiliation":[{"name":"Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Po","family":"Wang","sequence":"additional","affiliation":[{"name":"Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[{"name":"National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan;"},{"name":"Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; and"},{"name":"Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[{"name":"Departments of Oncology and"},{"name":"Internal Medicine,"},{"name":"Cancer Research Center, and"},{"name":"National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111810025239000_B1","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2001"},{"issue":"12","key":"2019111810025239000_B2","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2008-07-077982","article-title":"Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111810025239000_B3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1703","article-title":"Gastrointestinal lymphoma: where morphology meets molecular biology.","volume":"205","author":"Isaacson","year":"2005","journal-title":"J Pathol"},{"issue":"8871","key":"2019111810025239000_B4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0140-6736(93)91408-E","article-title":"The response of cells from low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue to Helicobacter pylori.","volume":"342","author":"Hussell","year":"1993","journal-title":"Lancet"},{"issue":"18","key":"2019111810025239000_B5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/jnci\/89.18.1350","article-title":"Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma.","volume":"89","author":"Neubauer","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2019111810025239000_B6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/annonc\/mdq182","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"21","author":"ESMO Guidelines Working Group","year":"2010","journal-title":"Ann Oncol"},{"issue":"22","key":"2019111810025239000_B7","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1200\/JCO.2001.19.22.4245","article-title":"Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach.","volume":"19","author":"Chen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111810025239000_B8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/jnci\/dji277","article-title":"Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.","volume":"97","author":"Chen","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2019111810025239000_B9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/gut.48.4.454","article-title":"Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori.","volume":"48","author":"Nakamura","year":"2001","journal-title":"Gut"},{"issue":"7","key":"2019111810025239000_B10","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1200\/JCO.2001.19.7.2041","article-title":"Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.","volume":"19","author":"Morgner","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8620","key":"2019111810025239000_B11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0140-6736(88)90574-0","article-title":"Classifying primary gut lymphomas.","volume":"2","author":"Isaacson","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"2019111810025239000_B12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/path.2117","article-title":"Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression.","volume":"211","author":"Kuo","year":"2007","journal-title":"J Pathol"},{"issue":"11","key":"2019111810025239000_B13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/00042737-200111000-00018","article-title":"Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication.","volume":"13","author":"Salam","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"2019111810025239000_B14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mge.2001.118647","article-title":"Regression of primary gastric diffuse large B-cell lymphoma after eradication of Helicobacter pylori.","volume":"54","author":"Sugimoto","year":"2001","journal-title":"Gastrointest Endosc"},{"issue":"4","key":"2019111810025239000_B15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gut.52.4.507","article-title":"Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection.","volume":"52","author":"Alsolaiman","year":"2003","journal-title":"Gut"},{"issue":"5","key":"2019111810025239000_B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/gut.51.5.621","article-title":"Diagnosis, treatment decisions, and follow-up in primary gastric lymphoma.","volume":"51","author":"Boot","year":"2002","journal-title":"Gut"},{"issue":"4","key":"2019111810025239000_B17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.gie.2008.05.021","article-title":"Gastric mucosa-associated lymphoid tissue lymphoma: a challenge for endoscopy.","volume":"68","author":"Fischbach","year":"2008","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"2019111810025239000_B18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpg.2009.12.003","article-title":"Diagnosis and staging in gastrointestinal lymphoma.","volume":"24","author":"Boot","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"2019111810025239000_B19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","article-title":"EGILS group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT.","volume":"60","author":"Ruskon\u00e9-Fourmestraux","year":"2011","journal-title":"Gut"},{"issue":"5","key":"2019111810025239000_B20","first-page":"1153","article-title":"Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach.","volume":"136","author":"Chan","year":"1990","journal-title":"Am J Pathol"},{"issue":"5","key":"2019111810025239000_B21","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0016-5085(97)70026-X","article-title":"Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance.","volume":"112","author":"de Jong","year":"1997","journal-title":"Gastroenterology"},{"issue":"7","key":"2019111810025239000_B22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/blood-2008-02-137513","article-title":"Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma.","volume":"112","author":"Kuo","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111810025239000_B23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"issue":"8","key":"2019111810025239000_B24","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection.","volume":"102","author":"Chey","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2019111810025239000_B25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1470-2045(02)00651-4","article-title":"Gastric MALT lymphoma: from aetiology to treatment.","volume":"3","author":"Du","year":"2002","journal-title":"Lancet Oncol"},{"issue":"8871","key":"2019111810025239000_B26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0140-6736(93)91409-F","article-title":"Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.","volume":"342","author":"Wotherspoon","year":"1993","journal-title":"Lancet"},{"key":"2019111810025239000_B27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7819-6-35","article-title":"High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature.","volume":"6","author":"Cavanna","year":"2008","journal-title":"World J Surg Oncol"},{"issue":"7","key":"2019111810025239000_B28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdh261","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.","volume":"15","author":"W\u00f6hrer","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111810025239000_B29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bpg.2009.12.005","article-title":"Long-term follow-up of gastric lymphoma after stomach conserving treatment.","volume":"24","author":"Fischbach","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"20","key":"2019111810025239000_B30","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.3748\/wjg.v16.i20.2526","article-title":"Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.","volume":"16","author":"Leopardo","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"9","key":"2019111810025239000_B31","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<1979::AID-CNCR1>3.0.CO;2-L","article-title":"Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor stages IE and IIE.","volume":"88","author":"Raderer","year":"2000","journal-title":"Cancer"},{"issue":"17","key":"2019111810025239000_B32","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.2006.06.1622","article-title":"Treatment of localized primary gastric lymphoma.","volume":"24","author":"W\u00f6hrer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111810025239000_B33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.7326\/0003-4819-131-2-199907200-00003","article-title":"Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled study.","volume":"131","author":"Steinbach","year":"1999","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019111810025239000_B34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gut.48.3.297","article-title":"Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.","volume":"48","author":"Ruskone-Fourmestaux","year":"2001","journal-title":"Gut"},{"issue":"1","key":"2019111810025239000_B35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gut.53.1.34","article-title":"Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.","volume":"53","author":"Fischbach","year":"2004","journal-title":"Gut"},{"issue":"4","key":"2019111810025239000_B36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1443-1661.2009.00896.x","article-title":"Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication.","volume":"21","author":"Tari","year":"2009","journal-title":"Dig Endosc"},{"issue":"21","key":"2019111810025239000_B37","article-title":"Final results of a multicenter phase II trial assessing the activity and efficacy of Helicobacter pylori-eradicating antibiotic therapy as exclusive treatment for patients with stage I-II1 diffuse large B-cell lymphoma of the stomach (the HGL-1 Trial) [abstract].","volume":"118","author":"Govi","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"2019111810025239000_B38","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood.V91.11.4321","article-title":"Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract.","volume":"91","author":"Barth","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111810025239000_B39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/gcc.1150","article-title":"Molecular-cytogenetic comparison of mucosa associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract.","volume":"31","author":"Barth","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111810025239000_B40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/path.2096","article-title":"Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.","volume":"211","author":"Barth","year":"2007","journal-title":"J Pathol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/21\/4838\/1352145\/zh802112004838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/21\/4838\/1352145\/zh802112004838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:49:00Z","timestamp":1574074140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/21\/4838\/29929\/Helicobacter-pylori-eradication-therapy-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,24]]},"references-count":40,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2012,5,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-01-404194","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717297825.792652832","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,24]]}}}